| 沙利度胺治疗特发性骨髓纤维化的研究进展 |
| |
| 引用本文： | 宋丽,陈嘉林. 沙利度胺治疗特发性骨髓纤维化的研究进展[J]. 中国医学科学院学报, 2009, 31(5). DOI: 10.3881/j.issn.1000-503X.2009.05.031 |
| |
| 作者姓名： | 宋丽 陈嘉林 |
| |
| 作者单位： | 中国医学科学院,北京协和医学院,北京协和医院普通内科,北京,100730 |
| |
| 摘 要： | 特发性骨髓纤维化是慢性骨髓增殖性疾病的一种.预后较差.造血干细胞移植能改善该病预后,但只适用于少数患者.目前多采用姑息性治疗措施,如雄激素、羟基脲等,疗效并不满意.沙利度胺兼具抗血管新生和抑制细胞因子的特性,在特发性骨髓纤维化的治疗中有一定疗效.
|
| 关 键 词： | 特发性骨髓纤维化 沙利度胺 治疗 |
Advances in Thalidomide Therapy for Idiopathic Myelofibrosis |
| |
| SONG Li,CHEN Jia-lin. Advances in Thalidomide Therapy for Idiopathic Myelofibrosis[J]. Acta Academiae Medicinae Sinicae, 2009, 31(5). DOI: 10.3881/j.issn.1000-503X.2009.05.031 |
| |
| Authors: | SONG Li CHEN Jia-lin |
| |
| Abstract: | Idiopathic myelofibros is a Philadelphia-negative chronic myeloproliferative disorder. Potentially curative therapies, such as stem-cell transplantation, are reserved only for a minority of patients. Currently palliative therapies such as androgen and hydroxycarbamide are commonly used but with poor results. Thalidomide has anti-angiogenic effect and also can inhibit cytokines, and therefore plays a certain role in the treatment of a subset of idiopathic myelofibros. |
| |
| Keywords: | idiopathic myelofibrosis thalidomide treatment |
| 本文献已被 万方数据 等数据库收录！ |
|
